• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

香港 COVID-19 轻症和中度患者康复后哮喘控制恶化。

Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong.

机构信息

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 4/F, Professorial Block, 102 Pokfulam Road, Pokfulam, Hong Kong, Special Administrative Region, China.

出版信息

Respir Res. 2023 Feb 14;24(1):53. doi: 10.1186/s12931-023-02363-z.

DOI:10.1186/s12931-023-02363-z
PMID:36788605
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9927038/
Abstract

BACKGROUND

While there are postulations that asthma is potentially associated with severe coronavirus disease 2019 (COVID-19), there has been conflicting results from studies on the impact mild-to-moderate COVID-19 on asthma control after recovery.

METHODS

A case control study on the association between mild-to-moderate COVID-19 and asthma control post infection was conducted. The primary outcome was a reduction in Asthma Control Test (ACT) score by ≥ 3 points post-COVID infection. The secondary outcomes included the change in ACT score, the proportion of patient with ACT score who dropped to ≤ 15 on enrolment visit and the need for escalation of asthma maintenance therapy.

RESULTS

Out of the total of 221 adult patients with asthma recruited, 111 had mild-to-moderate COVID-19 within 30 to 270 days prior to study enrolment. The adjusted odds ratio (aOR) for a reduction in ACT score by ≥ 3 points after COVID-19 was 3.105 (95% CI = 1.385-6.959, p = 0.006). The odds of escalation of asthma maintenance therapy by at least 1 Global Initiative for Asthma (GINA) step was 4.733 (95% CI = 1.151-19.467, p = 0.031) and asthma patient are more likely to become uncontrolled after COVID-19 [aOR = 5.509 (95% CI = 1.061-28.600, p = 0.042)].

CONCLUSION

Mild-to-moderate COVID-19 among asthma patients, upon recovery, was associated with worsening of asthma symptom, lower ACT score, a higher need for escalation of asthma maintenance therapy and more uncontrolled asthma.

摘要

背景

虽然有推测认为哮喘可能与严重的 2019 年冠状病毒病(COVID-19)有关,但关于轻度至中度 COVID-19 对康复后哮喘控制的影响,研究结果却存在矛盾。

方法

进行了一项关于轻度至中度 COVID-19 与感染后哮喘控制之间关联的病例对照研究。主要结局是 COVID 感染后哮喘控制测试(ACT)评分降低≥3 分。次要结局包括 ACT 评分的变化、入组时 ACT 评分降至≤15 的患者比例以及哮喘维持治疗升级的需要。

结果

在总共招募的 221 名成年哮喘患者中,有 111 名在研究入组前 30 至 270 天内患有轻度至中度 COVID-19。COVID-19 后 ACT 评分降低≥3 分的调整优势比(aOR)为 3.105(95%CI=1.385-6.959,p=0.006)。至少升级 1 个全球哮喘倡议(GINA)步骤的哮喘维持治疗升级的几率为 4.733(95%CI=1.151-19.467,p=0.031),并且 COVID-19 后哮喘患者更有可能变得无法控制[aOR=5.509(95%CI=1.061-28.600,p=0.042)]。

结论

哮喘患者在康复后患有轻度至中度 COVID-19 与哮喘症状恶化、ACT 评分降低、需要升级哮喘维持治疗以及更多无法控制的哮喘有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd23/9930310/b2ba1f0a66f2/12931_2023_2363_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd23/9930310/5307f98af8fb/12931_2023_2363_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd23/9930310/debf78f1f5c0/12931_2023_2363_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd23/9930310/b2ba1f0a66f2/12931_2023_2363_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd23/9930310/5307f98af8fb/12931_2023_2363_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd23/9930310/debf78f1f5c0/12931_2023_2363_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd23/9930310/b2ba1f0a66f2/12931_2023_2363_Fig3_HTML.jpg

相似文献

1
Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong.香港 COVID-19 轻症和中度患者康复后哮喘控制恶化。
Respir Res. 2023 Feb 14;24(1):53. doi: 10.1186/s12931-023-02363-z.
2
Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity.不同严重程度 COVID-19 感染后康复的慢性阻塞性肺疾病患者的结局。
Sci Rep. 2024 Jun 16;14(1):13881. doi: 10.1038/s41598-024-64670-9.
3
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
4
Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVID-19).哮喘,从轻症到重症,是轻症到重症 2019 冠状病毒病(COVID-19)的独立预后因素。
Clin Respir J. 2022 Apr;16(4):293-300. doi: 10.1111/crj.13480. Epub 2022 Feb 11.
5
A retrospective study regarding the influence of COVID-19 disease on asthma.一项关于 COVID-19 疾病对哮喘影响的回顾性研究。
BMC Pulm Med. 2023 Jan 17;23(1):22. doi: 10.1186/s12890-023-02309-7.
6
Asthma admission among children in Hong Kong during the first year of the COVID-19 pandemic.2019冠状病毒病大流行第一年香港儿童的哮喘住院情况。
Pediatr Pulmonol. 2022 Dec;57(12):3104-3110. doi: 10.1002/ppul.26141. Epub 2022 Sep 23.
7
The atopic march: from skin to the airways.特应性进程:从皮肤到气道。
Iran J Allergy Asthma Immunol. 2012 Mar;11(1):73-7.
8
The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey.作为全球哮喘防治创议(GINA)指南定义的哮喘控制指标预测工具的哮喘控制测试(ACT):一项跨国横断面调查分析
Prim Care Respir J. 2009 Mar;18(1):41-9. doi: 10.4104/pcrj.2009.00010.
9
Inhalant allergens as risk factors for the development and severity of mild-to-moderate asthma in Hong Kong Chinese children.吸入性变应原作为香港中国儿童轻至中度哮喘发生和严重程度的危险因素。
J Asthma. 2002 Jun;39(4):323-30. doi: 10.1081/jas-120002289.
10
Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria.使用 ACQ 和 ACT 与 GINA 标准对当前哮喘控制进行前瞻性评估。
Ann Allergy Asthma Immunol. 2011 Dec;107(6):474-9. doi: 10.1016/j.anai.2011.09.001. Epub 2011 Oct 5.

引用本文的文献

1
COVID-19 severity and risk of SARS-CoV-2-associated asthma exacerbation by time since booster vaccination: a longitudinal analysis of data from the COVIDENCE UK study.自加强疫苗接种以来的时间与新冠病毒相关哮喘加重的新冠病毒疾病严重程度及风险:来自英国COVIDENCE研究数据的纵向分析
BMJ Open Respir Res. 2025 May 15;12(1):e003158. doi: 10.1136/bmjresp-2025-003158.
2
Symptoms of Depression and Anxiety After COVID-19 Despite Systematic Telemedical Care: Results From the Prospective COVID-SMART Study.尽管有系统的远程医疗护理,新冠病毒感染后抑郁和焦虑症状:前瞻性COVID-SMART研究结果
Depress Anxiety. 2025 Apr 13;2025:9989990. doi: 10.1155/da/9989990. eCollection 2025.
3

本文引用的文献

1
Worsening of asthma control after COVID-19.新冠病毒感染后哮喘控制情况恶化。
Front Med (Lausanne). 2022 Sep 14;9:882665. doi: 10.3389/fmed.2022.882665. eCollection 2022.
2
Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease.免疫蛋白质组学分析揭示了持续性 COVID-19 呼吸道疾病患者气道中异常的免疫细胞调节。
Immunity. 2022 Mar 8;55(3):542-556.e5. doi: 10.1016/j.immuni.2022.01.017. Epub 2022 Jan 26.
3
Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVID-19).
Eosinophils and COVID-19: Insights into immune complexity and vaccine safety.
嗜酸性粒细胞与新冠病毒病:对免疫复杂性和疫苗安全性的见解
Clin Transl Allergy. 2025 Mar;15(3):e70050. doi: 10.1002/clt2.70050.
4
Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study.奈玛特韦/利托那韦与莫努匹韦在哮喘患者中的短期和长期比较疗效:一项队列研究
Respir Res. 2025 Feb 28;26(1):75. doi: 10.1186/s12931-025-03156-2.
5
Predictors of Cardiovascular Symptoms Among Long COVID Patients: Data from the Polish Long COVID Cardiovascular (PoLoCOV-CVD) Study.新冠长期症状患者心血管症状的预测因素:来自波兰新冠长期心血管(PoLoCOV-CVD)研究的数据。
J Clin Med. 2025 Feb 2;14(3):956. doi: 10.3390/jcm14030956.
6
Asthma control after recovery from mild to moderate COVID-19: from Omicron BA.2 to XBB- from a cohort in a university hospital in Hong Kong.轻度至中度新冠病毒感染康复后的哮喘控制:从奥密克戎BA.2到XBB——来自香港一家大学医院的队列研究
BMC Pulm Med. 2025 Feb 11;25(1):74. doi: 10.1186/s12890-025-03543-x.
7
COVID-19 and Long-term Risk of Ischemic Heart Disease in Asthma.哮喘患者中的新冠病毒疾病与缺血性心脏病的长期风险
Allergy Asthma Immunol Res. 2025 Jan;17(1):135-146. doi: 10.4168/aair.2025.17.1.135.
8
Clinical characteristics, anti-SARS-CoV-2 IgG titers, and inflammatory markers in individuals with post-COVID-19 condition in Kenya: a cross-sectional study.肯尼亚“新冠后遗症”患者的临床特征、抗 SARS-CoV-2 IgG 滴度和炎症标志物:一项横断面研究。
PeerJ. 2024 Jul 22;12:e17723. doi: 10.7717/peerj.17723. eCollection 2024.
9
Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity.不同严重程度 COVID-19 感染后康复的慢性阻塞性肺疾病患者的结局。
Sci Rep. 2024 Jun 16;14(1):13881. doi: 10.1038/s41598-024-64670-9.
10
Long COVID exhibits clinically distinct phenotypes at 3-6 months post-SARS-CoV-2 infection: results from the P4O2 consortium.新冠长期症状在感染SARS-CoV-2后3至6个月表现出临床上不同的表型:来自P4O2联盟的结果。
BMJ Open Respir Res. 2024 Apr 24;11(1):e001907. doi: 10.1136/bmjresp-2023-001907.
哮喘,从轻症到重症,是轻症到重症 2019 冠状病毒病(COVID-19)的独立预后因素。
Clin Respir J. 2022 Apr;16(4):293-300. doi: 10.1111/crj.13480. Epub 2022 Feb 11.
4
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.三种新型口服抗病毒药物(莫努匹韦、氟伏沙明和帕罗韦德)治疗 COVID-19 的疗效和安全性:一项荟萃分析。
Ann Med. 2022 Dec;54(1):516-523. doi: 10.1080/07853890.2022.2034936.
5
Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey.COVID-19 对哮喘患者的影响:一项来自英国全国范围调查的混合方法分析。
BMJ Open Respir Res. 2022 Jan;9(1). doi: 10.1136/bmjresp-2021-001056.
6
Hypotheses to explain the associations between asthma and the consequences of COVID-19 infection.解释哮喘与新冠病毒感染后果之间关联的假说。
Clin Exp Allergy. 2022 Jan;52(1):7-9. doi: 10.1111/cea.14021.
7
Asthma and COVID-19: an update.哮喘与 COVID-19:最新进展。
Eur Respir Rev. 2021 Dec 15;30(162). doi: 10.1183/16000617.0152-2021. Print 2021 Dec 31.
8
COVID-19 Infections and Asthma.COVID-19 感染与哮喘。
J Allergy Clin Immunol Pract. 2022 Mar;10(3):658-663. doi: 10.1016/j.jaip.2021.10.072. Epub 2021 Nov 25.
9
Long COVID or post COVID-19 syndrome.长期新冠或新冠后综合征。
Mult Scler Relat Disord. 2021 Oct;55:103268. doi: 10.1016/j.msard.2021.103268. Epub 2021 Sep 17.
10
Unaffected asthma control in children with mild asthma after COVID-19.新冠病毒感染后轻度哮喘儿童的哮喘控制未受影响。
Pediatr Pulmonol. 2021 Sep;56(9):3068-3070. doi: 10.1002/ppul.25567. Epub 2021 Jul 15.